Business Wire

SMITHS-DETECTION

10.10.2019 08:02:08 CEST | Business Wire | Press release

Share
Smiths Detection Showcases Biometric Checkpoint Solution at inter airport Europe 2019

Global threat detection and security technologies company, Smiths Detection is showcasing for the first time an integrated checkpoint solution at inter airport Europe 2019, which harnesses biometric technology to enable risk-based screening practices.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191009005541/en/

With air passenger growth predicted to double by 2037, the aviation industry will be challenged to support this capacity growth whilst providing operational efficiencies and meeting shifting passenger expectations of the airport experience.1 To cope with this growth, biometric technology is being increasingly adopted at airport Border Control gates, bag drop and boarding gates.

As leaders in providing checkpoint solutions to airports across the world, Smiths Detection has partnered with experts in the field of biometry to, for the first time, create a proof of concept which integrates biometric identity management solutions with class-leading screening solutions. Inter airport delegates are invited to experience the biometric capable checkpoint in action – which also employs Smiths Detection’s advanced CT scanner, HI-SCAN 6040 CTiX , the iCMORE Weapons automatic object recognition capability and the advanced tray return system, iLane.evo .

Biometrics is the ‘unique identifier’ for passengers, and through integration of biometrics directly into the checkpoint, passengers can be matched with their trays to enable real-time risk-based screening. Risk-based screening is designed to increase operational efficiency and effectiveness through continual risk assessments relevant to the individual passenger journey, resulting in shorter and easier journeys for passengers.

Through passenger and tray identification, new data insights can be gathered to inform decision making at airports - based on flights, airlines or destinations. Matching passengers with trays also enables the sharing of screening results with transit or arrival airports, and the combination of hold baggage and checkpoint screening results.

“At Smiths Detection, we’re dedicated to delivering a seamless passenger journey and we are very excited to be driving biometric checkpoint technology forward in a rapidly developing marketplace,” said Smiths Detection Vice President Europe, Africa and Marketing Tony Tielen . “As a trusted partner to airports across the world, we are working with the aviation industry to deliver risk-based screening at departure, transit and arrival airports to streamline the checkpoint journey to make it even safer and more efficient.”

“Biometrics is an urgently needed solution to provide seamless checkpoint security,” said Global Market Director Aviation, Richard Thompson . “Ever increasing air passenger traffic plus advances in biometrics, artificial intelligence and integrated screening technology mean that risk-based screening is now firmly on the fast track. We look forward to offering a preview of the checkpoint solution of the future to delegates at inter airport Europe 2019.”

Enquiries:

If you would like to speak with someone regarding this press release and/or preview this checkpoint solution, Smiths Detection will be presenting at Stand 410, Hall B6 at inter airport Europe.

References and data points:

  • At the beginning of 2018, SITA, the airlines technology supplier, reported that 77% of airports and 71% of airlines were planning major programs or R&D in biometric ID management over the next five years.
  • Airlines are responding to demands from passengers as 57% of passengers would "definitely use biometrics" if it helps them get quicker through the boarding process, according to SITA.
  • According to the IATA 2018 Passenger Survey , 45% of air travellers choose biometric identification as a replacement of their passport.
  • Over 65 percent of passenger’s were inclined towards sharing additional personal information to speed up their processing at the airport. Speed and convenience are paramount, according to IATA .

Recent press releases:

###

About Smiths Detection

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.

Our mission is to help make the world a safer place – and do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.

For more information visit http://www.smithsdetection.com .

About inter airport Europe

From 8 – 11 October 2019, inter airport Europe 2019, the 22nd International Exhibition for Airport Equipment, Technology, Design and Services will take place at the Munich Trade Fair Centre in Germany.

For manufacturers and suppliers of airport equipment, technology, design and services, inter airport Europe provides the opportunity to meet specialists from airports, airlines, air cargo carriers as well as aviation support from all over the world looking to invest in future-oriented, modern solutions for the interconnected airport. The world’s leading airport exhibition is renowned for covering the most comprehensive range of products and services for the entire airport: technology and services for ground handling, airport equipment, terminal operations, airport IT solutions and airport design.

For more information visit https://www.interairporteurope.com/welcome#/


1 https://www.iata.org/pressroom/pr/Pages/2018-10-24-02.aspx

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye